Afatinib cost effective for EGFRm+ NSCLC in France

Afatinib cost effective for EGFRm+ NSCLC in France PharmacoEconomics & Outcomes News 784, p8 - 12 Aug 2017 Afatinib cost effective for EGFRm+ NSCLC in France First-line treatment with afatinib is cost effective in France for patients with advanced epidermal growth- factor receptor mutation-positive non-small-cell lung cancer (EGFRm+ NSCLC), according to a study published in the Journal of Thoracic Oncology. Tyrokinase inhibitors are approved as first-line therapies for advanced NSCLC with an EGFR gene mutation. The cost effectiveness of two of these agents, afatinib and gefitinib, was compared using a partitioned survival model designed with data from the LUX-Lung 7 trial, the first prospective, multicentre, international, randomised, head-to-head trial of afatinib and gefitinib as first-line treatment for advanced EGFRm+ NSCLC. Direct medial costs were assessed over a 10-year time horizon, with costs estimated using official price lists, published data, fee schedules and questionnaires. A 4% discount rate was applied to costs and benefits. Afatinib was associated with a gain of 0.249 life-years and 0.17 quality-adjusted life-years (QALYs), compared with gefitinib, for the intention-to-treat (ITT) population. Subgroup analyses of patients with EGFR exon-19 deletion (del19) and EGFR exon-21 L858R mutation (L858R) supported this, with gains of 0.257 and 0.247 life-years, respectively, and 0.171 and 0.174 QALYs, respectively, for afatinib versus gefitinib. Afatinib had incremental cost-effectiveness ratios (ICERs) of €45 211, €38 970 and €52 518 for the ITT population, del19 subgroup and L858R subgroup, respectively, compared with gefitinib. Sensitivity analyses demonstrated that afatinib had a 100% probability of being cost effective for patients with common EGFR mutations at a willingness-to-pay (WTP) threshold of €70 000 per QALY. The authors noted that although cost-effectiveness analyses are mandatory in France for innovative drugs, there is no official WTP threshold. They concluded that "the World Health Organization-recommended conventional benchmark is an acceptable ICER-value range of 1–3 gross national product per capita, which would mean 2015 values of €32,735–€98,205 in France. The ICERs for all tested scenarios fell in that range". Chouaid C, et al. Cost-Effectiveness Analysis of Afatinib versus Gefitinib for first line treatment of advanced EGFR-Mutated Advanced Non-Small-Cell Lung Cancers. Journal of Thoracic Oncology : 24 Jul 2017 803262860 1173-5503/17/0784-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 12 Aug 2017 No. 784 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics & Outcomes News Springer Journals

Afatinib cost effective for EGFRm+ NSCLC in France

Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/afatinib-cost-effective-for-egfrm-nsclc-in-france-ZqIP2ESbRD
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Public Health
ISSN
1173-5503
eISSN
1179-2043
D.O.I.
10.1007/s40274-017-4219-x
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial